← Back to Search
‘The Same Old Story’: Thoughts On Authorized Doses Of Anticancer Drugs
F. Meriggi, A. Zaniboni
Published 2020 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Introduction Worldwide, tumours are currently one of the main causes of death with approximately 9.6 million deaths a year and an incidence of approximately 18.1 million new cases in 2018.1 Consequently, the prevention, diagnosis and treatment of cancer represent, more than ever before, goals towards which all international administrations are moving; however, the results are not always tangible and comforting. One of the causes of these total or partial failures has been identified as the absence of adequate nationwide awareness programmes regarding the lifestyles most likely to reduce the incidence of cancer, as well as a shortage of funding for research and for the distribution of the most innovative medicinal products to the whole population. On the other hand, cancer is a huge business opportunity for pharmaceutical companies around the world, even more now than in the past. A review by Hong and colleagues2 shows that in the United States between 2011 and 2016, spending on cancer drugs grew by over 50% (from US$26.8 to 42.1 billion). Although the introduction of immune checkpoint inhibitors has dramatically changed the treatment of a number of cancer types, they bring a host of new adverse effects to be managed and a further exponential increase in both direct and indirect costs. Researchers are exploring new strategies making it possible to deal in the years to come with what can be defined as an authentic politico-socio-economic emergency that is now well identified, also regarding the possibly over simplistic terminology such as the ‘financial toxicity’ of cancer treatments. The price, not merely in economic terms, that is likely to have to be paid is dramatic meaning that much of the world population, even in higher income countries, could be excluded from access to the most novel cancer treatments. One well consolidated, albeit far from decisive, pathway undertaken in an attempt to reduce costs is the authorization of biosimilars and generic medicines. Another option to be given careful attention is that of reconsidering (at equal efficacy) the authorized doses of certain medicinal products, especially those with higher costs, particularly when used on a large scale such as those indicated for the treatment of the most frequently terminal cancers.
This paper references
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
S. Jones (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
E. Van Cutsem (2006)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
M. Overman (2017)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
A. Paccagnella (2010)
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
H. Gurney (1996)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
S. Jones (2009)
Combination versus sequential single agent chemotherapy for metastatic breast cancer.
Rachel F Dear (2013)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
L. Saltz (2008)
Retrospective Analysis of Safety and Efficacy of Low-Dose Docetaxel 60 mg/m2 in Advanced Non–Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy
Y. Nakamura (2003)
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
E. Raymond (2011)
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
C. Smorenburg (2003)
A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non‐Small‐Cell Lung Cancer
A. Depierre (1991)
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
M. Ratain (1998)
Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)â€“An ACCRU Network study.
T. Bekaii-Saab (2018)
Abiraterone and increased survival in metastatic prostate cancer.
J. D. de Bono (2011)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
Abiraterone in metastatic prostate cancer without previous chemotherapy.
C. Ryan (2013)
Regorafenib dose optimization study (ReDOS): A phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC).
T. Bekaii-Saab (2016)
Population pharmacokinetics of doxorubicin
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma
S. Bracarda (2017)
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
E. Chatelut (2012)
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
M. Ratain (1991)
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
R. Szmulewitz (2018)
What is the effect of adjusting epirubicin doses for body surface area?
N. Dobbs (1998)
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
R. Mathijssen (2002)
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Peter C. Fong (2010)
Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
LB Saltz (2008)
Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing
M. Sawyer (2004)
Reporting harms more transparently in trials of cancer drugs
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
W. Eiermann (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
J. Bono (2010)
Spending on Antineoplastic Agents in the United States, 2011 to 2016.
Samuel J Hong (2018)
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
M. Markman (2000)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325
E Van Cutsem (2006)
Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd (2000)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
S. Bracarda (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
M. Ratain (2002)
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt (2017)
Advances in cancer
A Sparreboom (2009)
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group
E. Cutsem (2006)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
A. El-Khoueiry (2017)
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
M. Davidson (2019)
Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
J. Zalcberg (1998)
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
M. Posner (2007)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
F. Shepherd (2000)
Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
X. Zhao (2017)
Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual
D. Shepshelovich (2019)
Time Is Money: Optimizing the Scheduling of Nivolumab.
M. Ratain (2018)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
M. Mirza (2016)
The value meal: how to save $1,700 per month or more on lapatinib.
M. Ratain (2007)
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
F. Fossella (2000)
Firstand second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis
DA Goldstein (2015)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. James (2017)
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
C. Herbaux (2017)
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours
L. Devriese (2013)
Sources of interindividual variability.
K. Thummel (2014)
Dosing of anticancer agents in adults
KD Eaton (2018)
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
J. Radford (2016)
High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer
J. Stemmler (2005)
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
H. Hochster (2008)
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
W. Loos (2000)
Advances in Cancer Therapeutics
A. Sparreboom (2009)
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
A. Perez (2002)
etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (every 4 weeks) dosing schedule across multiple tumor types. Presented at American Association for Cancer
X Zhao (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber (2017)
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
J. Cassidy (1999)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
R. Motzer (2007)
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
P. Kellokumpu-Lehtinen (2013)
Abiraterone and increased survival in metastatic F Meriggi and A Zaniboni journals.sagepub.com/home/tam 7 prostate cancer
JS de Bono (2011)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
B. Cho (2017)
A phase II randomized study of lower dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC)
T S Bekaii-Saab (2018)
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
P. Francis (2008)
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
T. Le Chevalier (1994)
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
M. Eisenberger (2017)
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
F. D. de Jongh (2001)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
S. Baker (2002)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A. Grothey (2013)
Do older and younger patients derive similar survival benefits from novel oncology drugs? A systematic review and meta-analysis
V. Arciero (2018)
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
A. Patnaik (2015)
Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer
K. Fizazi (2017)
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
M. Etienne (1998)
Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
G. Freyer (2000)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
M. Valsecchi (2015)
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
D. Goldstein (2015)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
J. Vermorken (2007)
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
A. Felici (2002)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
Abiraterone and Increased Survival in Metastatic Prostate Cancer: de Bono JS, for the COU-AA-301 Investigators (Inst of Cancer Res and Royal Marsden Hosp, Sutton, Surrey, UK; et al) N Engl J Med 364:1995-2005, 2011 §
G. Andriole (2012)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
G. Demetri (2006)
Is dose normalization to weight or body surface area useful in adults?
L. Grochow (1990)
Bioequivalence of Two Methotrexate Formulations in Psoriatic and Cancer Patients
M. Teresi (1993)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
A. Shaw (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
R. Chen (2017)
Concomitant chemoradiotherapy versus induction docetaxel
A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (every 4 weeks) dosing schedule across multiple tumor types
Safety and dose modification for patients receiving niraparib
J. Berek (2018)
Novel Clinical Trial Designs for Innovative Therapies
J. Schellens (2009)
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
J. Tabernero (2004)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
J. Bruix (2017)
Population pharmacokinetics of doxorubicin, F Meriggi and A Zaniboni journals.sagepub.com/home/tam 11 etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
G Freyer (2000)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
I. Tannock (2004)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)